Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Zilucoplan Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides ...

The 2001 Corvette Z06 marked a turning point for America’s sports car, shifting it from a fast street machine into a factory ...

The trial is being conducted in patients with atypical hemolytic-uremic syndrome (aHUS) and will evaluate the effect of C5 knockdown on hematologic response and renal function, as well as safety and ...

To provide insight into the structural and functional properties of human complement component 5 (C5), we determined its crystal structure at a resolution of 3.1 Å. The core of C5 adopted a structure ...

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) reported positive results from a phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, ...

WATERTOWN, Mass. and NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve ...

As one of the most potent mediators of inflammation, the complement component C5a is a promising target for anti-inflammatory drugs. However, a drawback of using animal models to develop antagonists ...

Structure is everything. Lessons learned from the C5, C6 and C7 Corvettes is that the stiffer the chassis, the better the suspension can be tuned for improved handling. The C1 to C4 chassis were fine ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 2 clinical study with cemdisiran ...